RXC006 (Porcupine inhibitor)
Phase 1 Completed
Phase 1 Completed
About RXC006
Porcupine is a novel drug target that aims to address the issue of high unmet need in fibrosis and is a key enzyme in the Wnt signalling pathway. Aberrant Wnt signalling is involved in fibrogenesis, and inhibition of Wnt signalling is likely to prevent several mechanisms important for fibrotic disease progression. Current treatments for fibrosis provide limited benefit and there is an urgent need to develop new therapies to treat fibrotic conditions. Recent publications have shown that Porcupine inhibitors are effective in preclinical models and could be beneficial in the treatment of fibrotic indications, including renal, heart, lung and skin conditions.
RXC006 is a potent, selective, oral small molecule inhibitor of the enzyme, Porcupine, a key activator of Wnt-ligands in the Wnt signalling pathway. Our scientists demonstrated that RXC006/AZD5055 potently inhibits Porcupine, resulting in striking anti-fibrotic effects in animal models of kidney, liver and lung fibrosis. RXC006was initially nominated as a candidate for development in idiopathic pulmonary fibrosis and was further investigated in an undisclosed non-oncology indication. RXC006 is from a different chemical series to RXC004, and is protected by a separate composition of matter patent.
In August 2020, Redx Pharma signed an out licensing agreement for RXC006 with AstraZeneca, under which AstraZeneca had full responsibility for the clinical development of RXC006. AstraZeneca took RXC006(also known as AZD5055) forward into clinical development, targeting fibrotic diseases including idiopathic pulmonary fibrosis (IPF) and completed a Phase 1 trial during 2021. Following a strategic decision not to further develop this asset, the programme was transferred back to Redx in April 2026. Redx will assess opportunities to progress this programme.
Read the press releasePhase 1 Completed
About RXC006
Porcupine is a novel drug target that aims to address the issue of high unmet need in fibrosis and is a key enzyme in the Wnt signalling pathway. Aberrant Wnt signalling is involved in fibrogenesis, and inhibition of Wnt signalling is likely to prevent several mechanisms important for fibrotic disease progression. Current treatments for fibrosis provide limited benefit and there is an urgent need to develop new therapies to treat fibrotic conditions. Recent publications have shown that Porcupine inhibitors are effective in preclinical models and could be beneficial in the treatment of fibrotic indications, including renal, heart, lung and skin conditions.
RXC006 is a potent, selective, oral small molecule inhibitor of the enzyme, Porcupine, a key activator of Wnt-ligands in the Wnt signalling pathway. Our scientists demonstrated that RXC006/AZD5055 potently inhibits Porcupine, resulting in striking anti-fibrotic effects in animal models of kidney, liver and lung fibrosis. RXC006was initially nominated as a candidate for development in idiopathic pulmonary fibrosis and was further investigated in an undisclosed non-oncology indication. RXC006 is from a different chemical series to RXC004, and is protected by a separate composition of matter patent.
In August 2020, Redx Pharma signed an out licensing agreement for RXC006 with AstraZeneca, under which AstraZeneca had full responsibility for the clinical development of RXC006. AstraZeneca took RXC006(also known as AZD5055) forward into clinical development, targeting fibrotic diseases including idiopathic pulmonary fibrosis (IPF) and completed a Phase 1 trial during 2021. Following a strategic decision not to further develop this asset, the programme was transferred back to Redx in April 2026. Redx will assess opportunities to progress this programme.
Read the press release